Andrew Warmington has been writing about pharmaceuticals and related industries since becoming editor of Speciality Chemicals Magazine in 2002. His particular area of expertise is in the C(D)MO drug substance and CRO markets, plus some on the regulatory side developed during an 18-month stint with Chemical Watch. During this time, he has attended every CPhI Worldwide plus other key industry events, such as Informex/CPhI North America, DCAT Week and PharmaChem Outsourcing, where he has been a regular moderator of expert panels. He has also been a freelance proof-reader within the industry, notably for a major drug packaging company. Andrew has a PhD in History, and speaks French and Spanish, plus just enough Italian to get by. In his spare time, he is a would-be true crime writer, a TV quiz veteran and a sad cricket fan who would happily hibernate when the season is over…
Latest from Andrew Warmington
In Sept 2024, a new CMDO, DMX Pharma, emerged on the global market. Explore the benefits of this merger, from production capacity to cross-selling capability, regulatory expertise and their ambitious future plans.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.
Partnering has changed in many ways in the last 18 months. Financial markets have all but closed to start-ups and investors are consolidating asset bases in the expectation of relatively high inflation continuing for the next few years.
Restricted financial avenues raised many open questions at the recent LSX World Congress about the kind of deals that will shape biopharma pipelines in the coming 12-18 months.